Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Why Elacridar Can Raise Brain Drug Exposure
2026-11-22
Elacridar hydrochloride inhibits the efflux transporters BCRP and P-glycoprotein, but interpreting its effects requires separating absolute brain concentrations from the brain-to-plasma ratio. Those readouts can change for different biological reasons.
How Oleate Synthesis Shapes Pluripotent Cell Selectivity
2026-11-21
NSC 14613 is described as a selective eliminator of human pluripotent stem cells through inhibition of SCD1-dependent oleate synthesis. The proposed chain links lipid imbalance to endoplasmic-reticulum stress, reduced protein synthesis, and apoptosis, while the available documentation supports a mechanistic interpretation rather than a quantitative estimate of efficacy or universal cell-type selectivity.
How Dexlansoprazole Changes Acid Readouts
2026-11-20
How should researchers interpret Dexlansoprazole when proton-pump, cellular secretion, and bulk pH measurements do not show the same thing? The documented H+/K+ ATPase mechanism supports a clear causal framework, while the available product information does not establish quantitative potency or product-specific assay performance.
How PP7 Potency Maps to Influenza Polymerase
2026-11-20
PP7 is described as an inhibitor of the influenza A polymerase PB1–PB2 interaction. Its reported polymerase and cell-level potency values address different biological questions, so they support a mechanistic research hypothesis rather than one interchangeable measure of antiviral performance.
How Famotidine Changes Acid Readouts
2026-11-19
Famotidine is a competitive histamine H2-receptor antagonist whose documented mechanism helps connect receptor blockade with changes in gastric acid measurements. Interpreting those measurements requires separating histamine-dependent signaling from broader secretory activity, buffering, and material-related effects.
Acetoacetate Evidence: What It Can and Cannot Show
2026-11-19
The available publication explains isotope-labeling and mass-spectrometric interpretation for degarelix, not the biological efficacy of acetoacetate. This distinction matters when sodium 3-oxobutanoate is discussed in energy metabolism, diabetes, or ketoacidosis research.
Why CETP Assay Context Changes Potency
2026-11-18
Evacetrapib is documented as a selective CETP inhibitor with different IC50 values in purified-protein and plasma assays. Those values are not contradictory: they describe target inhibition in different biochemical environments, while the reported animal findings connect CETP inhibition with higher HDL but do not by themselves establish clinical benefit.
How to Interpret Leuprorelin Acetate Readouts
2026-11-18
A mechanism-based guide to connecting GnRH-receptor signaling with pituitary and peripheral hormone measurements while separating documented material characterization from product-specific biological validation.
(S)-(+)-Methoprene and JH Signaling in Locusts
2026-11-17
A 2025 locust study links juvenile hormone abundance, biosynthetic-gene expression, and coordinated miRNA regulation to vitellogenin production and ovarian growth. Its methoprene comparison supports downstream juvenile-hormone-like sufficiency, while leaving receptor-level pharmacology and the direct connection between miRNA control and analog response unresolved.
How Multiplex CRISPR Changes Causal Inference
2026-11-17
Multiplex CRISPR is powerful because simultaneous perturbation can expose gene interactions and structural mechanisms that single-target editing misses. The same property also complicates interpretation: DNA-damage responses, off-target activity and repair-generated structural variation can become inseparable from the intended biological effect.
Hydroxyzine 2HCl: Reading H1 Binding Values
2026-11-16
The documented 10 nM and 19 nM IC50 values show displacement of two radioligands from histamine H1 receptors. They support a receptor-level interpretation, but do not by themselves establish cellular signaling changes, anti-inflammatory effects, neurological outcomes, or clinical efficacy.
How Bupivacaine Blocks Nerve Signaling
2026-11-16
Bupivacaine’s local-anesthetic effect can be understood as a chain from sodium-channel inhibition to reduced nerve excitability. The documented description supports this class-level interpretation, while its qualitative claims about onset, duration, and surgical anesthesia are not a substitute for quantified comparative evidence.
How BIBP 3226 Links Receptors to Readouts
2026-11-15
BIBP 3226 trifluoroacetate is described as a non-peptide antagonist acting at NPY Y1 and NPFF receptors. Its documented binding values, cAMP mechanism, and rodent phenotypes illustrate how evidence progresses from molecular interaction to integrated physiology—and where those levels should not be treated as interchangeable.
How Does GSK1838705A Affect Cancer Signaling?
2026-11-14
GSK1838705A is documented as a small-molecule kinase inhibitor that acts on IGF-IR, the insulin receptor, and ALK. Its reported biochemical potency and antitumor effects occur at different levels of evidence, so cellular growth inhibition and tumor regression should be interpreted as model-dependent consequences rather than direct predictions of clinical activity.
How Bradykinin Links Receptors to Vascular Readouts
2026-11-13
Bradykinin (acetate) can produce different vascular, inflammatory, smooth-muscle and thrombotic readouts because receptor distribution and measurement level determine which part of its signaling network is observed. The documented mechanism supports a connected interpretation involving B2-receptor signaling, endothelial nitric oxide, prostacyclin, permeability and tissue-factor regulation, but does not establish one universal response across models.